Jilin Aodong Pharmaceutical Group Co Ltd banner

Jilin Aodong Pharmaceutical Group Co Ltd
SZSE:000623

Watchlist Manager
Jilin Aodong Pharmaceutical Group Co Ltd Logo
Jilin Aodong Pharmaceutical Group Co Ltd
SZSE:000623
Watchlist
Price: 18.87 CNY 1.07% Market Closed
Market Cap: ¥22.6B

EV/IC

0.7
Current
13%
More Expensive
vs 3-y average of 0.6

Enterprise Value to Invested Capital (EV/IC) ratio compares a company`s total enterprise value to the capital invested in its business. It shows how efficiently the company`s market value reflects the funds used to generate returns.

EV/IC
0.7
=
Enterprise Value
¥21.5B
/
Invested Capital
¥31.1B

Enterprise Value to Invested Capital (EV/IC) ratio compares a company`s total enterprise value to the capital invested in its business. It shows how efficiently the company`s market value reflects the funds used to generate returns.

EV/IC
0.7
=
Enterprise Value
¥21.5B
/
Invested Capital
¥31.1B

Valuation Scenarios

Jilin Aodong Pharmaceutical Group Co Ltd is trading above its 3-year average

If EV/IC returns to its 3-Year Average (0.6), the stock would be worth ¥16.71 (11% downside from current price).

Statistics
Positive Scenarios
2/4
Maximum Downside
-11%
Maximum Upside
+194%
Average Upside
87%
Scenario EV/IC Value Implied Price Upside/Downside
Current Multiple 0.7 ¥18.87
0%
3-Year Average 0.6 ¥16.71
-11%
5-Year Average 0.6 ¥17.15
-9%
Industry Average 2 ¥55.41
+194%
Country Average 1.9 ¥52.24
+177%

Forward EV/IC
Today’s price vs future invested capital

Not enough data available to calculate forward EV/IC

Peer Comparison

All Multiples
EV/IC
P/E
All Countries
Close
Market Cap EV/IC P/E
CN
Jilin Aodong Pharmaceutical Group Co Ltd
SZSE:000623
22.6B CNY 0.7 8.8
US
Eli Lilly and Co
NYSE:LLY
908.9B USD 8.9 36
US
Johnson & Johnson
NYSE:JNJ
547.1B USD 3.4 26
CH
Roche Holding AG
SIX:ROG
248.4B CHF 2.9 20.1
UK
AstraZeneca PLC
LSE:AZN
209.6B GBP 3.7 27.4
CH
Novartis AG
SIX:NOVN
221.1B CHF 2.9 20.7
US
Merck & Co Inc
NYSE:MRK
277.6B USD 2.6 31.1
IE
Endo International PLC
LSE:0Y5F
244.4B USD 56 -83.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.2T DKK 2.7 12.1
US
Pfizer Inc
NYSE:PFE
149.7B USD 1 19.3
US
Bristol-Myers Squibb Co
NYSE:BMY
118.9B USD -9.1 4 516.9

Market Distribution

Lower than 82% of companies in China
Percentile
18th
Based on 7 566 companies
18th percentile
0.7
Low
0 — 1.1
Typical Range
1.1 — 3.4
High
3.4 —
Distribution Statistics
China
Min 0
30th Percentile 1.1
Median 1.9
70th Percentile 3.4
Max 1 129 391.6

Jilin Aodong Pharmaceutical Group Co Ltd
Glance View

Market Cap
22.6B CNY
Industry
Pharmaceuticals

Jilin Aodong Pharmaceutical Group Co Ltd., nestled in the northeastern province of Jilin in China, has steadily crafted its narrative as a pivotal player in the pharmaceutical industry, blending traditional Chinese medicine with modern pharmaceuticals. The company began its journey focusing on the rich heritage of Chinese medicine, a reflection of the deep cultural roots in its origins, and gradually expanded into the realm of western pharmaceuticals. This dual approach has enabled Jilin Aodong to strategically position itself, catering to diverse market needs both domestically and internationally. By leveraging its expertise in research and development, the company has developed an array of products, including herbal medicine, chemical drugs, and biological pharmaceuticals, which are integral to its robust product portfolio. Driving its revenue engine is not just the sale of its diverse medicinal products, but also strategic investments and partnerships. Jilin Aodong's vertically integrated business model encompasses all aspects of pharmaceutical production, from sourcing raw materials to manufacturing and distribution, ensuring cost efficiency and quality control. Additionally, the company often engages in strategic alliances to amplify its market presence and innovation capabilities. By maintaining a balance between the time-tested efficacy of traditional medicine and the evolving demands of modern healthcare, Jilin Aodong establishes a unique market niche and secures a steady revenue stream, while continually seeking opportunities for expansion and innovation in the pharmaceutical landscape.

Intrinsic Value
16.47 CNY
Overvaluation 13%
Intrinsic Value
Price ¥18.87
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett